Fig. 5From: FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumaba Thyroid SUVmean at baseline and after three months for all patients. Patients that experienced a thyroid related-adverse event of Gr2 or greater are shown in various colors to distinguish them from patients that did not experience a thyroid-related adverse event (black). b Receiver operating characteristic curve showing the value of thyroid SUVmean at baseline for predicting which patients will go on to experience a thyroid-related adverse eventBack to article page